Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

The Coalition for Epidemic Preparedness Innovations (CEPI) granted funding to and Moderna for the development of a vaccine against the new coronavirus that emerged in China last month.

So far, the virus has killed nearly 25 people and infected 830 individuals.

 will use the CEPI grant to carry out preclinical and clinical development through Phase I human testing of its vaccine candidate, INO-4800, matched to the new coronavirus strain.

The company will work with Wistar Institute, GeneOne Life Science unit VGXI and Twist Bioscience to develop the vaccine.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Moderna intends to develop a messenger RNA (mRNA) vaccine for the virus. The company will use the CEPI funding to manufacture the vaccine.

To design the vaccine, Moderna partnered with the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

NIAID will perform investigational new drug (IND)-enabling studies and a Phase I clinical trial in the US.